These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36251249)

  • 1. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
    Bonaca MP; Szarek M; Debus ES; Nehler MR; Patel MR; Anand SS; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM
    Clin Cardiol; 2022 Dec; 45(12):1143-1146. PubMed ID: 36251249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
    Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
    Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
    J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
    Hess CN; Debus ES; Nehler MR; Anand SS; Patel MR; Szarek M; Capell WH; Hsia J; Beckman JA; Brodmann M; Diaz R; Habertheuer P; Leeper NJ; Powell RJ; Sillesen H; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM; Bonaca MP
    Circulation; 2021 Dec; 144(23):1831-1841. PubMed ID: 34637332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
    Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
    Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
    Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
    Hess CN; Szarek M; Anand SS; Bauersachs RM; Patel MR; Debus ES; Nehler MR; Capell WH; Beckman JA; Piazza G; Henkin S; Bura-Rivière A; Lawall H; Roztocil K; Hsia J; Muehlhofer E; Berkowitz SD; Haskell LP; Bonaca MP
    JAMA Netw Open; 2022 Jun; 5(6):e2215580. PubMed ID: 35731517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Belch JJ; Dormandy J; ; Biasi GM; Cairols M; Diehm C; Eikelboom B; Golledge J; Jawien A; Lepäntalo M; Norgren L; Hiatt WR; Becquemin JP; Bergqvist D; Clement D; Baumgartner I; Minar E; Stonebridge P; Vermassen F; Matyas L; Leizorovicz A
    J Vasc Surg; 2010 Oct; 52(4):825-33, 833.e1-2. PubMed ID: 20678878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
    Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
    Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
    Bauersachs RM; Szarek M; Brodmann M; Gudz I; Debus ES; Nehler MR; Anand SS; Patel MR; Hess CN; Capell WH; Rogers K; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP;
    J Am Coll Cardiol; 2021 Jul; 78(4):317-326. PubMed ID: 34010631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
    Hess CN; Baumgartner I; Anand SS; Nehler MR; Patel MR; Debus ES; Szarek M; Capell W; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM; Bonaca MP; Hsia J
    J Am Heart Assoc; 2022 Jun; 11(12):e024655. PubMed ID: 35699170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.
    Canonico ME; Low Wang CC; Hsia J; Debus ES; Nehler MR; Patel MR; Anand SS; Ycas J; Capell WH; Muehlhofer E; Haskell LP; Berkowitz SD; Bauersachs R; Bonaca MP
    J Am Coll Cardiol; 2024 Aug; 84(9):801-811. PubMed ID: 39168566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
    Hess CN; Patel MR; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Fanelli F; Yeh RW; Secemsky EA; Beckman JA; Mauri L; Govsyeyev N; Capell WH; Brackin T; Berkowitz SD; Muehlhofer E; Haskell LP; Hiatt WR; Bonaca MP
    J Am Coll Cardiol; 2021 Nov; 78(18):1768-1778. PubMed ID: 34711335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
    Yuan Z; Levitan B; Deng H; Szarek M; Bauersachs RM; Berkowitz SD; Haskell L; Barnathan ES; Bonaca MP
    J Am Heart Assoc; 2024 Apr; 13(8):e032782. PubMed ID: 38563380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.